ADC Therapeutics SA (ADCT) Form 8-K — Aug 13, 2026
ADC Therapeutics reported Q2 2026 net product revenues of $18.6 million, up from $18.1 million a year earlier, and narrowed its net loss to $16.6 million ($0.11 per share) from $56.6 million in Q2 2025, driven by a 29% reduction in total operating expenses. Cash of $219.1 million is expected to fund operations at least into 2028. The FDA raised substantial concerns at a pre-sBLA meeting about the benefit-risk of the LOTIS-5 Phase 3 trial, citing an imbalance in Grade 5 events in the context of marginal treatment benefit. The company is reassessing its regulatory path while ZYNLONTA remains on accelerated approval in 3L+ DLBCL, with a strategy update promised in the near future.
Key figures
- Revenue
- 18634000
- Guidance
- Cash runway expected at least into 2028; ZYNLONTA revenue growth anticipated starting in 2027
- Revenue Yoy
- +3.0%
- Total Assets
- 279379000
- Cash Position
- 219107000
- Cash dec 31 2025 usd
- 261338000
- Total opex q2 2026 usd
- 44662000
- Workforce reduction pct
- 17
- Adjusted opex q2 2026 usd
- 37221000
- Lotis7 enrollment patients
- 100
- Annualized cost savings usd
- 10000000
- R and d expense q2 2026 usd
- 17366000
- Total opex reduction q2 yoy
- 29%
- Weighted avg shares q2 2026
- 155016023
- Adjusted net loss q2 2026 usd
- 16312000
- Deferred royalty obligation usd
- 299543000
- Q2 2025 net product revenue usd
- 18085000
- Q2 2026 net product revenue usd
- 18634000
- Us 2l plus dlbcl market by 2030
- ~$3Bn (company estimate)
- Restructuring charge q2 2026 usd
- 2674000
- License revenues royalties q2 2026 usd
- 614000
- Six month 2026 net product revenue usd
- 38667000
Price after filing
Close on the filing date to close N calendar days later (from $1.18). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.